Release Date: 2024-06-19

Enzalutamide Therapy for Metastatic Prostate Cancer

Turgay Turan (Author), Yunus Erol Bozkurt (Author)

Release Date: 2024-06-19

Enzalutamide (ENZ), a potent androgen receptor pathway inhibitor, gained FDA approval in 2012 for metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel chemotherapy. It exhibits high affinity to the androgen receptor (AR), disrupting AR signaling crucial for prostate cancer growth. Notably, ENZ’s mechanism inhibits AR nuclear translocation and exerts apoptotic effects, distinct from older antiandrogens like bicalutamide. [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page79
    Last Page88
    DOIhttps://doi.org/10.69860/nobel.9786053359142.7
    Page Count10
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Enzalutamide (ENZ), a potent androgen receptor pathway inhibitor, gained FDA approval in 2012 for metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel chemotherapy. It exhibits high affinity to the androgen receptor (AR), disrupting AR signaling crucial for prostate cancer growth. Notably, ENZ’s mechanism inhibits AR nuclear translocation and exerts apoptotic effects, distinct from older antiandrogens like bicalutamide. Clinical trials demonstrate ENZ’s efficacy across various stages of prostate cancer, from metastatic hormone-sensitive disease to non-metastatic CRPC, prolonging overall and radiographic progression-free survival. ENZ’s favorable outcomes in combination therapies highlight its role in advancing prostate cancer treatment paradigms.

    Turgay Turan (Author)
    MD, Associate Professor of Urology, Izmir Democracy University
    https://orcid.org/0000-0002-4951-6396
    3Born in 1978 in Tokat, I completed my medical education at 19 Mayıs University Faculty of Medicine from 1997 to 2003. Following this, I pursued my specialization in urology at Health Sciences University, Umraniye Training and Research Hospital, Department of Urology from 2006 to 2011. In 2019, I earned the title of Associate Professor in the field of Urology. Since 2022, I have been serving as a Urology Specialist at the Department of Urology, Faculty of Medicine, Izmir Democracy University. I have expertise in Urooncology and Endourology and have authored several articles in these fields. Throughout my career, I have been dedicated to advancing medical knowledge and improving patient care, while also teaching and mentoring medical students and residents. I am proficient in advanced surgical techniques and clinical research, and I am committed to providing specialized urological care to patients.

    Yunus Erol Bozkurt (Author)
    MD, Manisa Merkez Efendi State Hospital
    https://orcid.org/0000-0002-9894-9489
    3Born in 1988 in Malatya, I completed my medical education at Ege University Faculty of Medicine from 2006 to 2012. Subsequently, I pursued specialization in urology at the Department of Urology, Manisa Celal Bayar University Faculty of Medicine, spanning from 2013 to 2020. Since 2020, I have served as a urology specialist at Manisa Merkez Efendi State Hospital. With expertise in andrology and functional urology, I have authored articles in these fields.

    • Mukherji D, Pezaro CJ, De-Bono JS. MDV3100 for the treatment of PC. Expert Opin Investig Drugs. 2012 Feb;21(2):227-33.

    • Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL; PC Foundation/Department of Defense PC Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant PC: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-46.

    • Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002 Jul 1;20(13):3001-15.

    • Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in PC. Expert Rev Endocrinol Metab. 2010 Sep;5(5):753-764.

    • Heinlein CA, Chang C. Androgen receptor in PC. Endocr Rev. 2004 Apr;25(2):276- 308.

    • Knudsen KE, Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced PC. Expert Rev Endocrinol Metab 2011; 6: 483–93.

    • Scher HI, Heller G. Clinical states in PC: toward a dynamic model of disease progression. Urology. 2000 Mar;55(3):323-7.

    • Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members; European Society for Medical Oncology. PC: ESMO Consensus Conference Guidelines 2012. Ann Oncol. 2013 May;24(5):1141-62.

    • Attar RM, Takimoto CH, Gottardis MM. Castration-resistant PC: locking up the molecular escape routes. Clin Cancer Res. 2009 May 15;15(10):3251-5.

    • Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced PC. Science. 2009 May 8;324(5928):787-90.

    • Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic PC: a mechanism for castration-resistant tumor growth. Cancer Res. 2008 Jun 1;68(11):4447-54.

    • XTANDI (enzalutamide). Summary of Product Characteristics, 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002639/WC500144996.pdf. Accessed April 2015

    • XTANDI (enzalutamide). Prescribing Information, 2014. Available at: https://www.astellas.us/docs/12A005-ENZ-WPI.PDF. Accessed April 2015

    • Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and PC Trials Group. Enzalutamide with Standard FirstLine Therapy in Metastatic PC. N Engl J Med. 2019 Jul 11;381(2):121-131.

    • Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive PC. J Clin Oncol. 2019 Nov 10;37(32):2974-2986.

    • Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D’Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA. NCCN Guidelines® Insights: PC, Version 1.2023. J Natl Compr Canc Netw. 2022 Dec;20(12):1288-1298.

    • Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and PC Trials Group (ANZUP). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive PC Treated with Enzalutamide and Androgen Deprivation Therapy. Eur Urol. 2021 Sep;80(3):275279.

    • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in PC after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97.

    • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Enzalutamide in metastatic PC before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33.

    • Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Improved Outcomes with Enzalutamide in Biochemically Recurrent PC. N Engl J Med. 2023 Oct 19;389(16):1453-1465.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!